NASDAQ:PAVM - PAVmed Stock Price, Forecast & News

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

PAVmed Inc (NASDAQ:PAVM) issued its earnings results on Thursday, November, 21st. The company reported ($0.09) earnings per share (EPS) for the quarter. View PAVmed's Earnings History.

PAVmed is scheduled to release their next quarterly earnings announcement on Thursday, April 2nd 2020. View Earnings Estimates for PAVmed.

1 Wall Street analysts have issued 1 year target prices for PAVmed's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PAVmed's stock price to reach $3.00 in the next year. This suggests a possible upside of 102.7% from the stock's current price. View Analyst Price Targets for PAVmed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

Press coverage about PAVM stock has trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PAVmed earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for PAVmed.

PAVmed saw a increase in short interest in December. As of December 31st, there was short interest totalling 928,100 shares, an increase of 65.8% from the December 15th total of 559,700 shares. Based on an average trading volume of 450,900 shares, the short-interest ratio is presently 2.1 days. Currently, 3.5% of the company's shares are sold short. View PAVmed's Current Options Chain.

Some companies that are related to PAVmed include Soliton (SOLY), Repro-Med Systems (REPR), Repro Med Systems (KRMD), iCAD (ICAD), Venus Concept (VERO), TELA Bio (TELA), Cytosorbents (CTSO), Spectral Medical (EDTXF), BRAINSWAY LTD/S (BWAY), Liquidia Technologies (LQDA), BeyondAirInc . (XAIR), Neuronetics (STIM), Nephros (NEPH), Nephros (NEPHD) and AIT Therapeutics (AITB).

Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Agile Therapeutics (AGRX), Aptose Biosciences (APTO), Tonix Pharmaceuticals (TNXP), AT&T (T), Inovio Pharmaceuticals (INO), Opko Health (OPK), Amarin (AMRN) and Axsome Therapeutics (AXSM).

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAVM stock can currently be purchased for approximately $1.48.

PAVmed has a market capitalization of $56.40 million. PAVmed employs 9 workers across the globe.View Additional Information About PAVmed.

The official website for PAVmed is http://www.pavmed.com/.

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]